Fingerprick blood samples to measure serum natalizumab concentrations

Alyssa A. Toorop, Maurice Steenhuis, Floris C. Loeff, Suzanne S. Weijers, Joep Killestein, Theo Rispens, Zoé L. E. van Kempen

Research output: Contribution to journalArticleAcademicpeer-review


Background: Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis. Objective: In light of personalized extended dosing, in which treatment intervals are prolonged to a concentration cut-off, it would be preferable to measure natalizumab drug concentrations in capillary blood. Methods: In this cross-sectional study in patients treated with intravenous (IV) natalizumab, capillary blood samples by fingerprick and venous blood samples were collected in 30 participants prior to IV administration of natalizumab. Results: Natalizumab concentrations were similar with a mean bias of −0.36 μg/mL (95% CI: 1.3 to −2 μg/mL). Conclusions: This study shows that physicians can monitor natalizumab drug concentrations by a fingerprick, which could be used for personalized extended dosing.
Original languageEnglish
Early online date2022
Publication statusE-pub ahead of print - 2022


  • Multiple sclerosis
  • capillary
  • extended interval dosing
  • fingerprick
  • natalizumab

Cite this